Switching to Dolutegravir/Lamivudine Two-Drug Regimen: Durability and Virologic Outcomes by Age, Sex, and Race in Routine US Clinical Care.

Gerald PieroneLaurence BrunetJennifer S FuscoCassidy E HenegarSupriya SarkarJean Van WykVani VannappagariMichael B WohlfeilerGregory P Fusco

Published in: HIV/AIDS (Auckland, N.Z.) (2024)

This descriptive study demonstrates that DTG/3TC 2DR is an effective and well-tolerated treatment option for people with HIV with a viral load <50 copies/mL at switch, regardless of their age, sex, or race.

Keyphrases

antiretroviral therapy
hiv infected patients
hiv infected
hiv positive
human immunodeficiency virus
hiv aids
healthcare
palliative care
hepatitis c virus
hiv testing
quality improvement
emergency department
type diabetes
metabolic syndrome
weight loss
skeletal muscle
health insurance